Search

Search Constraints

You searched for: Author/Creator Jovanovic, Ana

Search Results

2. 149 A novel internally validated risk prediction model for adverse cardiac outcome in fabry disease. (6th June 2022)

3. D A novel internally validated risk prediction model for adverse cardiac outcome in fabry disease. (6th June 2022)

6. MO034A SUBGROUP ANALYSIS OF FEMALE PATIENTS IN A PHASE 3 OPEN-LABEL STUDY TO ASSESS THE SAFETY AND EFFICACY OF PEGUNIGALSIDASE ALFA IN PATIENTS WITH FABRY DISEASE PREVIOUSLY TREATED WITH AGALSIDASE ALFA. (29th May 2021)

7. Native T1 mapping versus CMR Feature Tracking (FT) derived strain analysis for the assessment of cardiac disease manifestation in Anderson Fabry. Issue 1 (December 2016)

8. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. Issue 4 (10th November 2016)

9. Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female patients with Fabry disease: A multicenter Fabry Registry study. Issue 4 (12th April 2018)